Antibody Levels to Trypanosoma Cruzi in Infected Patients with and without Evidence of Chronic Chagas' Disease

Renato d'A. GusmāoLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Medicine, Faculty of Medicine, Federal University of Goias, Bethesda, Maryland 20205, Brazil

Search for other papers by Renato d'A. Gusmāo in
Current site
Google Scholar
PubMed
Close
,
Joffre M. RezendeLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Medicine, Faculty of Medicine, Federal University of Goias, Bethesda, Maryland 20205, Brazil

Search for other papers by Joffre M. Rezende in
Current site
Google Scholar
PubMed
Close
,
Anis RassiLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Medicine, Faculty of Medicine, Federal University of Goias, Bethesda, Maryland 20205, Brazil

Search for other papers by Anis Rassi in
Current site
Google Scholar
PubMed
Close
,
Albert A. GamLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Medicine, Faculty of Medicine, Federal University of Goias, Bethesda, Maryland 20205, Brazil

Search for other papers by Albert A. Gam in
Current site
Google Scholar
PubMed
Close
, and
Franklin A. NevaLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Medicine, Faculty of Medicine, Federal University of Goias, Bethesda, Maryland 20205, Brazil

Search for other papers by Franklin A. Neva in
Current site
Google Scholar
PubMed
Close
Restricted access

Antibody levels to Trypanosoma cruzi were compared in asymptomatic individuals infected with the parasite as well as those with different forms of chronic Chagas' disease of varying severity. The following three serologic tests were used: complement fixation, direct agglutination with previous treatment of the serum with 2-mercaptoethanol, and the enzymelinked immunosorbent assay. The clinical groups tested included individuals with (a) a positive serology but no symptoms and without evidence of chronic disease (indeterminate form); (b) mega disease (groups I, II, III, and IV); (c) cardiomyopathy (mild, moderate, and severe); and (d) those with both mega disease and cardiomyopathy (combined form). The mean enzyme-linked immunosorbent assay and complement fixation antibody levels among the various clinical groups showed no statistical differences. With the direct agglutination test patients with mega disease and those with severe cardiomyopathy had slightly higher mean titers than patients in the indeterminate group and those with mild or moderate cardiomyopathy. While there may be possible reasons for these differences, the biological relevance of the findings was concluded to be of dubious significance.

Author Notes

Present address: The Johns Hopkins University, Department of Pathobiology, Tropical Medicine Center, Baltimore, Maryland 21205.

Save